BoAn Biotech

BoAn Biotech, a holding subsidiary of Luye Pharma Group, is an integrated biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic antibodies, with a focus on oncology, autoimmune diseases, pain management, and endocrine disorders. The company’s antibody discovery activities are centered around three major platforms: the transgenic mouse platform for fully human antibodies combined with phage display technology, the bispecific T-cell engager (BiTE) technology platform, and the antibody-drug conjugate (ADC) technology platform. Currently, BoAn Biotech has built a portfolio comprising more than 10 innovative antibodies protected by international intellectual property rights and eight biosimilars. In addition, the company is actively strategizing around cutting-edge technologies such as CAR-T. According to incomplete statistics, there have been seven financing rounds in the healthcare sector to which BoAn Biotech belongs this year. BoAn Biotech possesses a fully integrated industrial chain covering antibody generation and lead optimization, cell line development and process development, technology transfer, pilot-scale production, and commercial manufacturing. Meanwhile, the company is actively deploying resources around frontier technologies, committed to developing safer, more effective, and affordable CAR-T products, including CAR-T cell therapy products for advanced solid tumors prepared using non-viral vectors, as well as next-generation universal and controllable CAR-T therapies. Beyond the Chinese market, BoAn Biotech is also conducting biological product development in the United States and European Union markets.